Table 3: laboratory and clinical response to ustekinumab
收藏NIAID Data Ecosystem2026-03-12 收录
数据链接：
官方服务：
资源简介：
laboratory and clinical response to ustekinumab
应用场景：
创建时间：
2021-05-26
相关数据集
Seroconversion patient number from (I) biologics-naïve patients (II) non-biologics-naïve patients.
Seroconversion patient number from (I) biologics-naïve patients (II) non-biologics-naïve patients.
NIAID Data Ecosystem10
Inner-City Anti-IgE Therapy for Asthma (ICATA/ICAC-08)
The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alon
Immunology Database and Analysis Portal2025-10-30 更新10
Dataset from A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
NIAID Data Ecosystem00
Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial
To compare the effect of treat-to-target-based escalations in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics on clinical disease activity and magnetic resonance
NIAID Data Ecosystem10
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
DataCite Commons2025-02-10 更新00
